Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Carboplatin and Paclitaxel for Endometrial Cancer
NCT02549209Phase 2Completed
- Start
- Aug 2017
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in endometrial adenocarcinoma. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
endometrial adenocarcinoma
Beyond the preview
Go deeper on NCT02549209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02549209.